Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q86YS7
UPID:
C2CD5_HUMAN
Alternative names:
C2 domain-containing phosphoprotein of 138 kDa
Alternative UPACC:
Q86YS7; B4DJ03; B4DRN7; B7ZLL0; F5H2A1; F5H5R1; O60280; Q17RY7; Q7Z619; Q86SU3
Background:
C2 domain-containing protein 5, also known as a 138 kDa phosphoprotein, plays a crucial role in insulin-stimulated glucose transport. It facilitates the translocation of the glucose transporter SLC2A4/GLUT4 from glucose storage vesicles to the plasma membrane in adipocytes. This process is essential for maintaining glucose homeostasis, with the protein binding to phospholipid membranes in a calcium-dependent manner to ensure optimal membrane fusion.
Therapeutic significance:
Understanding the role of C2 domain-containing protein 5 could open doors to potential therapeutic strategies. Its pivotal function in glucose transport and metabolism positions it as a key target for addressing metabolic disorders, including diabetes.